$7.50
0.091.21%
At close: -
$7.48
-0.02-0.27%
After Hours: 6:44 PM EDT
Comments
Loading...
Intellia Therapeutics Analyst Ratings and Price Targets | NASDAQ:NTLA | Benzinga
Intellia Therapeutics Inc has a consensus price target of $49.5 based on the ratings of 26 analysts. The high is $116 issued by EF Hutton on February 24, 2023. The low is $11 issued by Morgan Stanley on January 27, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Truist Securities, and Barclays on March 5, 2025, March 4, 2025, and February 28, 2025, respectively. With an average price target of $35.33 between HC Wainwright & Co., Truist Securities, and Barclays, there's an implied 372.37% upside for Intellia Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Truist Securities
Barclays
Citigroup
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Intellia Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/05/2025 | Buy Now | 301.07% | HC Wainwright & Co. | Mitchell Kapoor43% | → $30 | Initiates | → Buy | Get Alert |
| 03/04/2025 | Buy Now | 568.45% | Truist Securities | Joon Lee75% | $90 → $50 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 247.59% | Barclays | Gena Wang50% | $55 → $26 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 87.17% | Citigroup | David Lebowitz52% | $12 → $14 | Maintains | Neutral | Get Alert |
| 02/28/2025 | Buy Now | 568.45% | Wells Fargo | Yanan Zhu36% | $60 → $50 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 809.09% | Chardan Capital | Geulah Livshits43% | $91 → $68 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 73.8% | JP Morgan | Brian Cheng36% | $45 → $13 | Downgrade | Overweight → Neutral | Get Alert |
| 01/27/2025 | Buy Now | 47.06% | Morgan Stanley | Terence Flynn66% | $56 → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/14/2025 | Buy Now | 60.43% | Goldman Sachs | Salveen Richter52% | $20 → $12 | Maintains | Neutral | Get Alert |
| 01/13/2025 | Buy Now | 434.76% | Oppenheimer | Jay Olson61% | $60 → $40 | Maintains | Outperform | Get Alert |
| 01/10/2025 | Buy Now | 702.14% | Wells Fargo | Yanan Zhu36% | $70 → $60 | Maintains | Overweight | Get Alert |
| 01/10/2025 | Buy Now | 568.45% | BMO Capital | Kostas Biliouris32% | $70 → $50 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 1103.21% | Canaccord Genuity | Whitney Ijem43% | $90 → $90 | Maintains | Buy | Get Alert |
| 11/18/2024 | Buy Now | 835.83% | Wells Fargo | Yanan Zhu36% | $80 → $70 | Maintains | Overweight | Get Alert |
| 11/18/2024 | Buy Now | 87.17% | Wedbush | David Nierengarten59% | $14 → $14 | Reiterates | Neutral → Neutral | Get Alert |
| 11/18/2024 | Buy Now | 1116.58% | Chardan Capital | Geulah Livshits43% | $88 → $91 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | 702.14% | Oppenheimer | Jay Olson61% | $70 → $60 | Maintains | Outperform | Get Alert |
| 11/08/2024 | Buy Now | 635.29% | Barclays | Gena Wang50% | $76 → $55 | Maintains | Overweight | Get Alert |
| 10/25/2024 | Buy Now | 154.01% | Citigroup | David Lebowitz52% | $25 → $19 | Maintains | Neutral | Get Alert |
| 10/25/2024 | Buy Now | 167.38% | Goldman Sachs | Salveen Richter52% | $31 → $20 | Maintains | Neutral | Get Alert |
| 10/25/2024 | Buy Now | 140.64% | Baird | Jack Allen 35% | $24 → $18 | Maintains | Neutral | Get Alert |
| 10/24/2024 | Buy Now | 1076.47% | Chardan Capital | Geulah Livshits43% | $94 → $88 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 621.93% | RBC Capital | Luca Issi36% | $54 → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 09/17/2024 | Buy Now | 448.13% | Jones Trading | Debanjana Chatterjee13% | → $41 | Initiates | → Buy | Get Alert |
| 09/11/2024 | Buy Now | 755.61% | Stifel | Dae Gon Ha46% | $80 → $64 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 635.29% | JP Morgan | Brian Cheng36% | $61 → $55 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | 621.93% | RBC Capital | Luca Issi36% | $60 → $54 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | 875.94% | Canaccord Genuity | Whitney Ijem43% | $73 → $73 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 768.98% | Cantor Fitzgerald | Rick Bienkowski26% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 1504.28% | Truist Securities | Joon Lee75% | $120 → $120 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 768.98% | Cantor Fitzgerald | Rick Bienkowski26% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2024 | Buy Now | 768.98% | Cantor Fitzgerald | Rick Bienkowski26% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 287.7% | Citigroup | David Lebowitz52% | $31 → $29 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 835.83% | BMO Capital | Kostas Biliouris32% | $62 → $70 | Maintains | Outperform | Get Alert |
| 04/23/2024 | Buy Now | 287.7% | Wedbush | David Nierengarten59% | $29 → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 327.81% | Goldman Sachs | Salveen Richter52% | → $32 | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 875.94% | Canaccord Genuity | Whitney Ijem43% | $72 → $73 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen32% | — | Initiates | → Peer Perform | Get Alert |
| 11/13/2023 | Buy Now | 835.83% | Oppenheimer | Jay Olson61% | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/13/2023 | Buy Now | 1036.36% | Morgan Stanley | Terence Flynn66% | $90 → $85 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 728.88% | BMO Capital | Kostas Biliouris32% | $64 → $62 | Maintains | Outperform | Get Alert |
| 11/10/2023 | Buy Now | 835.83% | RBC Capital | Luca Issi36% | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/10/2023 | Buy Now | 1718.18% | Goldman Sachs | Salveen Richter52% | $157 → $136 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 662.03% | Raymond James | Steven Seedhouse58% | $78 → $57 | Maintains | Outperform | Get Alert |
| 09/13/2023 | Buy Now | 768.98% | Cantor Fitzgerald | Rick Bienkowski26% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 768.98% | Cantor Fitzgerald | Rick Bienkowski26% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 768.98% | Cantor Fitzgerald | Rick Bienkowski26% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | Buy Now | 1103.21% | Barclays | Gena Wang50% | $86 → $90 | Maintains | Overweight | Get Alert |
| 08/07/2023 | Buy Now | 768.98% | Canaccord Genuity | Whitney Ijem43% | $66 → $65 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | 1330.48% | Chardan Capital | Geulah Livshits43% | → $107 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 434.76% | Citigroup | David Lebowitz52% | $44 → $40 | Maintains | Neutral | Get Alert |
| 08/04/2023 | Buy Now | 1103.21% | Barclays | Gena Wang50% | $148 → $90 | Maintains | Overweight | Get Alert |
| 06/13/2023 | Buy Now | 1116.58% | B of A Securities | Greg Harrison40% | $89 → $91 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 1330.48% | Chardan Capital | Geulah Livshits43% | $111 → $107 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 916.04% | Credit Suisse | Richard Law41% | → $76 | Reiterates | Outperform → Outperform | Get Alert |
| 05/08/2023 | Buy Now | 488.24% | Citigroup | David Lebowitz52% | $39 → $44 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 1103.21% | Oppenheimer | Jay Olson61% | $93 → $90 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | 1049.73% | Morgan Stanley | Terence Flynn66% | $83 → $86 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 755.61% | BMO Capital | Kostas Biliouris32% | $57 → $64 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 942.78% | Raymond James | Steven Seedhouse58% | $94 → $78 | Maintains | Outperform | Get Alert |
| 04/13/2023 | Buy Now | 782.35% | Canaccord Genuity | Whitney Ijem43% | → $66 | Initiates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | 956.15% | JP Morgan | Brian Cheng36% | $82 → $79 | Maintains | Overweight | Get Alert |
| 03/21/2023 | Buy Now | 621.93% | Bernstein | William Pickering36% | → $54 | Initiates | → Outperform | Get Alert |
| 03/14/2023 | Buy Now | 662.03% | BMO Capital | Kostas Biliouris32% | $54 → $57 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/27/2023 | Buy Now | 1383.96% | Chardan Capital | Geulah Livshits43% | $129 → $111 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 916.04% | Credit Suisse | Richard Law41% | $88 → $76 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 1143.32% | Oppenheimer | Jay Olson61% | $115 → $93 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 461.5% | Baird | Jack Allen 35% | $58 → $42 | Maintains | Neutral | Get Alert |
| 02/24/2023 | Buy Now | 1450.8% | EF Hutton | Michael King44% | $123 → $116 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 1156.68% | Raymond James | Steven Seedhouse58% | $124 → $94 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 795.72% | Cantor Fitzgerald | Rick Bienkowski26% | → $67 | Initiates | → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 421.39% | Citigroup | David Lebowitz52% | $48 → $39 | Upgrade | Sell → Neutral | Get Alert |
| 01/23/2023 | Buy Now | 1022.99% | SVB Leerink | Mani Foroohar48% | $86 → $84 | Maintains | Outperform | Get Alert |
| 01/19/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 01/04/2023 | Buy Now | 1504.28% | Wells Fargo | Yanan Zhu36% | $135 → $120 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 1076.47% | Credit Suisse | Richard Law41% | $109 → $88 | Maintains | Outperform | Get Alert |
| 12/02/2022 | Buy Now | 1049.73% | SVB Leerink | Mani Foroohar48% | $90 → $86 | Maintains | Outperform | Get Alert |
| 11/15/2022 | Buy Now | 1624.6% | Chardan Capital | Geulah Livshits43% | $121 → $129 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 1544.39% | EF Hutton | Michael King44% | $130 → $123 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 1009.63% | Morgan Stanley | Terence Flynn66% | $84 → $83 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 1557.75% | Raymond James | Steven Seedhouse58% | $127 → $124 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 1357.22% | Credit Suisse | Richard Law41% | $101 → $109 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 1517.65% | Chardan Capital | Geulah Livshits43% | $146 → $121 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 1637.97% | EF Hutton | Michael King44% | → $130 | Initiates | → Buy | Get Alert |
| 10/11/2022 | Buy Now | 1022.99% | Morgan Stanley | Terence Flynn66% | → $84 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | Buy Now | 1036.36% | JP Morgan | Brian Cheng36% | → $85 | Initiates | → Overweight | Get Alert |
| 09/19/2022 | Buy Now | 1383.96% | JMP Securities | Silvan Tuerkcan44% | $106 → $111 | Maintains | Market Outperform | Get Alert |
| 09/19/2022 | Buy Now | 2012.3% | SVB Leerink | Mani Foroohar48% | $152 → $158 | Maintains | Outperform | Get Alert |
| 09/01/2022 | Buy Now | 568.45% | Citigroup | David Lebowitz52% | → $50 | Initiates | → Sell | Get Alert |
| 08/05/2022 | Buy Now | 1932.09% | SVB Leerink | Mani Foroohar48% | $155 → $152 | Maintains | Outperform | Get Alert |
| 08/05/2022 | Buy Now | 1851.87% | Chardan Capital | Geulah Livshits43% | $172 → $146 | Maintains | Buy | Get Alert |
| 06/17/2022 | Buy Now | 621.93% | BMO Capital | Kostas Biliouris32% | → $54 | Initiates | → Market Perform | Get Alert |
| 06/16/2022 | Buy Now | 835.83% | B of A Securities | Greg Harrison40% | → $70 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 2306.42% | Goldman Sachs | Salveen Richter52% | $206 → $180 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 1637.97% | Oppenheimer | Jay Olson61% | $160 → $130 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 1370.59% | JMP Securities | Silvan Tuerkcan44% | $165 → $110 | Maintains | Market Outperform | Get Alert |
| 05/06/2022 | Buy Now | 1210.16% | Credit Suisse | Richard Law41% | $100 → $98 | Maintains | Outperform | Get Alert |
| 05/06/2022 | Buy Now | 1303.74% | Raymond James | Steven Seedhouse58% | $181 → $105 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | 1236.9% | Credit Suisse | Richard Law41% | → $100 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Intellia Therapeutics (NTLA) stock?
The latest price target for Intellia Therapeutics (NASDAQ:NTLA) was reported by HC Wainwright & Co. on March 5, 2025. The analyst firm set a price target for $30.00 expecting NTLA to rise to within 12 months (a possible 301.07% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intellia Therapeutics (NTLA)?
The latest analyst rating for Intellia Therapeutics (NASDAQ:NTLA) was provided by HC Wainwright & Co., and Intellia Therapeutics initiated their buy rating.
When was the last upgrade for Intellia Therapeutics (NTLA)?
The last upgrade for Intellia Therapeutics Inc happened on March 14, 2023 when BMO Capital raised their price target to $57. BMO Capital previously had a market perform for Intellia Therapeutics Inc.
When was the last downgrade for Intellia Therapeutics (NTLA)?
The last downgrade for Intellia Therapeutics Inc happened on February 28, 2025 when JP Morgan changed their price target from $45 to $13 for Intellia Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Intellia Therapeutics (NTLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.
Is the Analyst Rating Intellia Therapeutics (NTLA) correct?
While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a initiated with a price target of $0.00 to $30.00. The current price Intellia Therapeutics (NTLA) is trading at is $7.48, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.